we conclude that the combination of methotrexate and cyclosporine is superior to cyclosporine alone in the prevention of acute graft versus host disease after marrow transplantation for leukemia , and that this therapy may have a beneficial effect on long-term survival .
C0005961
marrow
C0087111
therapy